keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/29352072/sex-and-race-differences-in-lifetime-risk-of-heart-failure-with-preserved-ejection-fraction-and-heart-failure-with-reduced-ejection-fraction
#1
Ambarish Pandey, Wally Omar, Colby Ayers, Michael LaMonte, Liviu Klein, Norrina Allen, Lewis H Kuller, Philip Greenland, Charles Eaton, John S Gottdiener, Donald Lloyd-Jones, Jarett D Berry
Background -Lifetime risk of heart failure has been estimated to range from 20% to 46% in diverse sex and race groups. However, lifetime risk estimates for the two HF phenotypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), is not known. Methods -Participant-level data from 2 large prospective cohort studies, the Cardiovascular Health Study (CHS) and the Multiethnic Study of Atherosclerosis (MESA), were pooled excluding individuals with prevalent HF at baseline...
January 19, 2018: Circulation
https://www.readbyqxmd.com/read/29350254/sacubitril-valsartan-for-heart-failure-with-reduced-left-ventricular-ejection-fraction-a%C3%A2-retrospective-cohort-study
#2
R De Vecchis, C Ariano, G Di Biase, M Noutsias
BACKGROUND: The combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II-IV. METHODS: Our retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II-III HF vs...
January 19, 2018: Herz
https://www.readbyqxmd.com/read/29343997/hospitalisation-in-patients-with-heart-failure-with-preserved-ejection-fraction
#3
REVIEW
Shane Nanayakkara, Hitesh C Patel, David M Kaye
Heart failure is highly prevalent with more than 50% of cases being patients with a preserved ejection fraction (HFPEF), a figure that is projected to increase due to the changing risk factor landscape, in particular the ageing population. Overall mortality is similar to patients with heart failure with reduced ejection fraction (HFREF), as are the rates of hospitalisation. Patients with HFPEF have more comorbid conditions with fewer therapeutic options available. In this review, we explore the epidemiology of hospitalisation of HFPEF, the impact of current treatment modalities, and the potential of future therapies...
2018: Clinical Medicine Insights. Cardiology
https://www.readbyqxmd.com/read/29333094/left-ventricular-diastolic-and-systolic-dyssynchrony-and-dysfunction-in-heart-failure-with-preserved-ejection-fraction-and-a-narrow-qrs-complex
#4
Shuang Liu, Zhengyu Guan, Xuanyi Jin, Pingping Meng, Yonghuai Wang, Xianfeng Zheng, Dalin Jia, Chunyan Ma, Jun Yang
Aims: Mechanical dyssynchrony has been reported in heart failure with preserved ejection fraction (HFpEF), with a majority of patients having a narrow QRS complex; however, whether any benefit is observed with restoration of dyssynchrony remains unclear. We sought to assess left ventricular (LV) dyssynchrony and function in HFpEF and elucidate the underlying mechanisms that may account for HFpEF. Methods: Seventy-eighty patients with a narrow QRS complex including 47 with HFpEF, 31 with heart failure with reduced ejection fraction (HFrEF) patients, and 29 with asymptomatic left ventricular diastolic dysfunction (LVDD) were recruited...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29327797/potassium-and-the-use-of-renin-angiotensin-aldosterone-system-inhibitors-in-heart-failure-with-reduced-ejection-fraction-data-from-biostat-chf
#5
Joost C Beusekamp, Jasper Tromp, Haye H van der Wal, Stefan D Anker, John G Cleland, Kenneth Dickstein, Gerasimos Filippatos, Pim van der Harst, Hans L Hillege, Chim C Lang, Marco Metra, Leong L Ng, Piotr Ponikowski, Nilesh J Samani, Dirk J van Veldhuisen, Aeilko H Zwinderman, Patrick Rossignol, Faiez Zannad, Adriaan A Voors, Peter van der Meer
BACKGROUND: Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Whether it affects the use of renin-angiotensin-aldosterone system inhibitors and thereby negatively impacts outcome is unknown. Therefore, we investigated the association between potassium and uptitration of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) and its association with outcome. METHODS AND RESULTS: Out of 2516 patients from the BIOSTAT-CHF study, potassium levels were available in 1666 patients with HFrEF...
January 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29322198/association-of-cardiovascular-biomarkers-with-incident-heart-failure-with-preserved-and-reduced-ejection-fraction
#6
Rudolf A de Boer, Matthew Nayor, Christopher R deFilippi, Danielle Enserro, Vijeta Bhambhani, Jorge R Kizer, Michael J Blaha, Frank P Brouwers, Mary Cushman, Joao A C Lima, Hossein Bahrami, Pim van der Harst, Thomas J Wang, Ron T Gansevoort, Caroline S Fox, Hanna K Gaggin, Willem J Kop, Kiang Liu, Ramachandran S Vasan, Bruce M Psaty, Douglas S Lee, Hans L Hillege, Traci M Bartz, Emelia J Benjamin, Cheeling Chan, Matthew Allison, Julius M Gardin, James L Januzzi, Sanjiv J Shah, Daniel Levy, David M Herrington, Martin G Larson, Wiek H van Gilst, John S Gottdiener, Alain G Bertoni, Jennifer E Ho
Importance: Nearly half of all patients with heart failure have preserved ejection fraction (HFpEF) as opposed to reduced ejection fraction (HFrEF), yet associations of biomarkers with future heart failure subtype are incompletely understood. Objective: To evaluate the associations of 12 cardiovascular biomarkers with incident HFpEF vs HFrEF among adults from the general population. Design, Setting, and Participants: This study included 4 longitudinal community-based cohorts: the Cardiovascular Health Study (1989-1990; 1992-1993 for supplemental African-American cohort), the Framingham Heart Study (1995-1998), the Multi-Ethnic Study of Atherosclerosis (2000-2002), and the Prevention of Renal and Vascular End-stage Disease study (1997-1998)...
January 10, 2018: JAMA Cardiology
https://www.readbyqxmd.com/read/29320510/adipose-tissue-atgl-modifies-the-cardiac-lipidome-in-pressure-overload-induced-left-ventricular-failure
#7
Janek Salatzki, Anna Foryst-Ludwig, Kajetan Bentele, Annelie Blumrich, Elia Smeir, Zsofia Ban, Sarah Brix, Jana Grune, Niklas Beyhoff, Robert Klopfleisch, Sebastian Dunst, Michal A Surma, Christian Klose, Michael Rothe, Frank R Heinzel, Alexander Krannich, Erin E Kershaw, Dieter Beule, P Christian Schulze, Nikolaus Marx, Ulrich Kintscher
Adipose tissue lipolysis occurs during the development of heart failure as a consequence of chronic adrenergic stimulation. However, the impact of enhanced adipose triacylglycerol hydrolysis mediated by adipose triglyceride lipase (ATGL) on cardiac function is unclear. To investigate the role of adipose tissue lipolysis during heart failure, we generated mice with tissue-specific deletion of ATGL (atATGL-KO). atATGL-KO mice were subjected to transverse aortic constriction (TAC) to induce pressure-mediated cardiac failure...
January 10, 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29318651/effect-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-pharmacokinetics-and-pharmacodynamics-of-a-single-dose-of-furosemide
#8
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou, Gangadhar Sunkara, Thomas H Langenickel
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be co-administrated with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two- period, single-sequence study in healthy subjects (N=28). METHODS: All subjects received 40 mg oral single dose furosemide during period 1 followed by washout of 2 days...
January 9, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29315510/developing-drugs-for-heart-failure-with-reduced-ejection-fraction-hfref-what-have-we-learned-from-clinical-trials
#9
REVIEW
Markus Hinder, B Alexander Yi, Thomas H Langenickel
No abstract text is available yet for this article.
January 9, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29305104/heart-failure-with-mid-range-ejection-fraction-in-patients-admitted-to-internal-medicine-departments-findings-from-the-rica-registry
#10
María Esther Guisado-Espartero, Prado Salamanca-Bautista, Óscar Aramburu-Bodas, Alicia Conde-Martel, José Luis Arias-Jiménez, Pau Llàcer-Iborra, Melitón Francisco Dávila-Ramos, Yolanda Cabanes-Hernández, Luis Manzano, Manuel Montero-Pérez-Barquero
AIM: To improve the knowledge on characteristics, treatment and prognosis in patients with heart failure (HF) and mid-range ejection fraction discharged after an acute HF episode. METHODS: We prospectively included and followed 2753 patients admitted with HF to Internal Medicine units. Patients were classified according to ejection fraction (EF) into three strata: reduced, EF <40% (HFrEF); mid-range EF 40-49% (HFmrEF); and preserved EF ≥50% (HFpEF). Clinical, echocardiographic, laboratory data and treatment at discharge were recorded and the groups were compared...
January 2, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29305071/effectiveness-of-guideline-consistent-heart-failure-drug-prescriptions-at-hospital-discharge-on-1-year-mortality-results-from-the-epical2-cohort-study
#11
Amandine Busson, Nathalie Thilly, Hervé Laborde-Castérot, François Alla, Ziyad Messikh, Isabelle Clerc-Urmes, Alexandre Mebazaa, Marc Soudant, Nelly Agrinier
BACKGROUND: We aimed to assess the effectiveness of recommended drug prescriptions at hospital discharge on 1-year mortality in patients with heart failure (HF) and reduced ejection fraction (HFREF). MATERIALS AND METHODS: We used data from the EPICAL2 cohort study. HF patients ≥18years old with left ventricular ejection fraction (LVEF) <40% and alive at discharge were included and followed up for mortality. Socio-demographic, clinical and therapeutic data were collected at admission...
January 2, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29300945/heart-failure-subgroups-hfref-hfmref-and-hfpef-with-or-without-mitral-regurgitation
#12
Thomas F Lüscher
No abstract text is available yet for this article.
January 1, 2018: European Heart Journal
https://www.readbyqxmd.com/read/29300199/recent-advances-in-heart-failure
#13
Mahwash Kassi, Bashar Hannawi, Barry Trachtenberg
PURPOSE OF REVIEW: Acute heart failure continues to be a challenge as there is limited benefit of numerous agents that have been tested. Cardiac resynchronization therapy remains standard of care, yet timing and need for implantable cardiac defibrillator has been brought into question with the recent randomized trials. Several recent advances have been made towards management of heart failure both in drug and device therapy. The purpose of this review is to provide an update on the most important recent studies on heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF)...
January 2, 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29297194/red-cell-distribution-width-and-its-relationship-with-global-longitudinal-strain-in-patients-with-heart-failure-with-reduced-ejection-fraction-a-study-using-two-dimensional-speckle-tracking-echocardiography
#14
Elif Eroglu, Alev Kilicgedik, Gokhan Kahveci, Ruken Bengi Bakal, Cevat Kirma
BACKGROUND: Red cell distribution width (RDW) is a measurement of size variability of the red blood cells and has been shown to be a powerful predictor of prognosis in heart failure (HF). Recently, global longitudinal strain (GLS) emerged as a more accurate marker of left ventricular (LV) systolic function. AIM: We aimed to assess the relationship between RDW and standard echocardiographic parameters and left ventricular global strain measured by two-dimensional (2D) speckle tracking echocardiography in patients with HF with reduced EF (HFrEF)...
January 3, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29284577/distinct-myocardial-targets-for-diabetes%C3%A2-therapy-in-heart-failure-with-preserved-or%C3%A2-reduced-ejection-fraction
#15
REVIEW
Walter J Paulus, Elisa Dal Canto
Noncardiac comorbidities such as diabetes mellitus (DM) have different outcomes in heart failure with preserved ejection fraction (HFpEF) compared with heart failure with reduced ejection fraction (HFrEF). These different outcomes are the result of distinct myocardial effects of DM on HFpEF and HFrEF, which relate to different mechanisms driving myocardial remodeling in each heart failure phenotype. Myocardial remodeling is driven by microvascular endothelial inflammation in HFpEF and by cardiomyocyte cell death in HFrEF...
January 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29283405/the-impact-of-bronchodilator-therapy-on-systolic-heart-failure-with-concomitant-mild-to-moderate-copd
#16
Mahoto Kato, Kazuo Komamura, Masafumi Kitakaze, Atsushi Hirayama
In older adults, chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure with reduced ejection fraction (HFrEF), and the high prevalence of this combination suggests that customized treatment is highly necessary in patients with COPD and HFrEF. To investigate whether the treatment of COPD with tiotropium, an anticholinergic bronchodilator, reduces the severity of heart failure in patients with HFrEF complicated by mild to moderate COPD, forty consecutive participants were randomly divided into two groups and enrolled in a crossover design study...
December 28, 2017: Diseases (Basel)
https://www.readbyqxmd.com/read/29279134/mortality-after-an-episode-of-acute-heart-failure-in-a-cohort-of-patients-with-intermediate-ventricular-function-global-analysis-and-relationship-with-admission-department
#17
Òscar Miró, Patricia Javaloyes, Víctor Gil, Javier Jacob, Pablo Herrero-Puente, Francisco Javier Martín-Sánchez, Eva Salvo, Héctor Alonso, María Ángeles Juan Gómez, John Parissis, Pere Llorens
BACKGROUND AND OBJECTIVE: To compare the outcome of patients with acute heart failure (AHF) with a mid-range left ventricular ejection fraction (HFmrEF) with patients with a reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction. PATIENTS AND METHOD: A prospective observational study included patients diagnosed with AHF in 41 emergency departments. Patients were divided into 3 groups: HFrEF<40%, HFmrEF 40-49% and HFpEF≥50%. We collected 38 independent variables and the adjusted and crude all-cause mortality at one-year in the HFmrEF group was compared with that of the HFrEF and HFpEF groups...
December 23, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29273666/clinical-characteristics-one-year-change-in-ejection-fraction-and-long-term-outcomes-in-patients-with-heart-failure-with-mid-range-ejection-fraction-a-multicentre-prospective-observational-study-in-catalonia-spain
#18
Nuria Farré, Josep Lupon, Eulàlia Roig, Jose Gonzalez-Costello, Joan Vila, Silvia Perez, Marta de Antonio, Eduard Solé-González, Cristina Sánchez-Enrique, Pedro Moliner, Sonia Ruiz, C Enjuanes, Sonia Mirabet, Antoni Bayés-Genís, Josep Comin-Colet
OBJECTIVES: The aim of this study was to analyse baseline characteristics and outcome of patients with heart failure and mid-range left ventricular ejection fraction (HFmrEF, left ventricular ejection fraction (LVEF) 40%-49%) and the effect of 1-year change in LVEF in this group. SETTING: Multicentre prospective observational study of ambulatory patients with HF followed up at four university hospitals with dedicated HF units. PARTICIPANTS: Fourteen per cent (n=504) of the 3580 patients included had HFmrEF...
December 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/29262399/sacubitril-valsartan-in-clinical-practice-a-report-of-2-cases
#19
Eugenio Cosentino
Following the results of the PARADIGM-HF trial, the European Society of Cardiology (ESC) guidelines recommend sacubitril/valsartan to replace ACE inhibitors in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy and who fit trial criteria. However, the optimal use of sacubitril/valsartan in clinical practice needs further investigation. We report here the cases of 2 patients with HFrEH successfully treated with sacubitril/valsartan in our daily practice...
2017: Cardiology
https://www.readbyqxmd.com/read/29251818/acutely-decompensated-heart-failure-with-preserved-and-reduced-ejection-fraction-present-with-comparable-haemodynamic-congestion
#20
Lucas N L Van Aelst, Mattia Arrigo, Rui Placido, Eiichi Akiyama, Nicolas Girerd, Faiez Zannad, Philippe Manivet, Patrick Rossignol, Marc Badoz, Malha Sadoune, Jean-Marie Launay, Etienne Gayat, Carolyn S P Lam, Alain Cohen-Solal, Alexandre Mebazaa, Marie-France Seronde
AIMS: Congestion is a central feature of acute heart failure (HF) and its assessment is important for clinical decisions (e.g. tailoring decongestive treatments). It remains uncertain whether patients with acute HF with preserved ejection fraction (HFpEF) are comparably congested as in acute HF with reduced EF (HFrEF). This study assessed congestion, right ventricular (RV) and renal dysfunction in acute HFpEF, HFrEF and non-cardiac dyspnoea. METHODS AND RESULTS: We compared echocardiographic and circulating biomarkers of congestion in 146 patients from the MEDIA-DHF study: 101 with acute HF (38 HFpEF, 41 HFrEF, 22 HF with mid-range ejection fraction) and 45 with non-cardiac dyspnoea...
December 18, 2017: European Journal of Heart Failure
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"